Who are Liposomal doxorubicin hydrochloride's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pemetrexed + Cisplatin /Carboplatin, S-1 [Tegafur/Oteracil/gimeracil], cytarabine and mitoxantrone, S-1 plus Cisplatin, TS-1 and cisplatin, cetuximab + cisplatin + vinorelbine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/liposomal-doxorubicin-hydrochloride.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Liposomal doxorubicin hydrochloride — Competitive Intelligence Brief

Liposomal doxorubicin hydrochloride (Liposomal doxorubicin hydrochloride) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antineoplastic agent. Area: Oncology.

marketed Antineoplastic agent DNA and topoisomerase II Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Liposomal doxorubicin hydrochloride (Liposomal doxorubicin hydrochloride) — Cephalon, Inc..

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Liposomal doxorubicin hydrochloride TARGET	Liposomal doxorubicin hydrochloride	Cephalon, Inc.	marketed	Antineoplastic agent	DNA and topoisomerase II
Pemetrexed + Cisplatin /Carboplatin	Pemetrexed + Cisplatin /Carboplatin	Jiangsu Hansoh Pharmaceutical Co., Ltd.	phase 3	Antineoplastic agent	Thymidylate synthase, Dihydrofolate reductase, Glycinamide ribonucleotide formyltransferase
S-1 [Tegafur/Oteracil/gimeracil]	S-1 [Tegafur/Oteracil/gimeracil]	AstraZeneca	phase 3	Antineoplastic agent	Thymidylate synthase
cytarabine and mitoxantrone	cytarabine and mitoxantrone	Pfizer	phase 3	Antineoplastic agents
S-1 plus Cisplatin	S-1 plus Cisplatin	Taiho Pharmaceutical Co., Ltd.	phase 3	Antineoplastic agents	Thymidylate synthase, DNA
TS-1 and cisplatin	TS-1 and cisplatin	Taiho Pharmaceutical Co., Ltd.	phase 3	Antineoplastic agent	DNA
cetuximab + cisplatin + vinorelbine	cetuximab + cisplatin + vinorelbine	Merck KGaA, Darmstadt, Germany	phase 3	Antineoplastic agents	EGFR

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antineoplastic agent class)

Acrotech Biopharma Inc. · 1 drug in this class
Asan Medical Center · 1 drug in this class
AstraZeneca · 1 drug in this class
Beijing Biostar Pharmaceuticals Co., Ltd. · 1 drug in this class
Cephalon, Inc. · 1 drug in this class
Jiangsu Hansoh Pharmaceutical Co., Ltd. · 1 drug in this class
Seattle Project Corporation · 1 drug in this class
Taiho Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Liposomal doxorubicin hydrochloride — Competitive Intelligence Brief. https://druglandscape.com/ci/liposomal-doxorubicin-hydrochloride. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab